Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Jeffrey Zonder
Anti-Tumor Activity of Selective Inhibitor of Nuclear Export (SINE) Compounds, Is Enhanced in Non-Hodgkin Lymphoma Through Combination With mTOR Inhibitor and Dexamethasone
Cancer Letters
Cancer Research
Oncology
Daratumumab Proves Safe and Highly Effective in AL Amyloidosis
British Journal of Haematology
Hematology
Related publications
The BCL2 Inhibitor Venetoclax Is Active in Non-Hodgkin Lymphoma
Cancer Discovery
Oncology
Antitumor Activity of Selective MEK1/2 Inhibitor AZD6244 in Combination With PI3K/mTOR Inhibitor BEZ235 in Gefitinib-Resistant NSCLC Xenograft Models
Journal of Experimental and Clinical Cancer Research
Cancer Research
Oncology
Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185
PLoS ONE
Multidisciplinary
Pre-Clinical Pharmacology of AZD3965, a Selective Inhibitor of McT1: DLBCL, NHL and Burkitt’s Lymphoma Anti-Tumor Activity
Oncotarget
Oncology
Selective Inhibitors of Nuclear Export (SINE)– A Novel Class of Anti-Cancer Agents
Journal of Hematology and Oncology
Cancer Research
Oncology
Hematology
Molecular Biology
Verdinexor (KPT-335), a Selective Inhibitor of Nuclear Export, Reduces RSV Replication in Vitro
Journal of Virology
Insect Science
Immunology
Microbiology
Virology
Combination Treatment With Doxorubicin and microRNA-21 Inhibitor Synergistically Augments Anticancer Activity Through Upregulation of Tumor Suppressing Genes
International Journal of Oncology
Cancer Research
Oncology
Preclinical Evaluation of the Novel, Orally Bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Spontaneous Canine Cancer: Results of a Phase I Study
PLoS ONE
Multidisciplinary
The Dual PI3K/mTOR Inhibitor, NVP-BEZ235, Is Efficacious Against Follicular Lymphoma
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
